Open AccessPharmacodynamics and Pharmacokinetics of Higher-Dose, Double-Bolus Eptifibatide in Percutaneous Coronary Intervention
Author(s) -
Ian C. Gilchrist,
J.Conor O’Shea,
Teddy Kosoglou,
Lisa K. Jennings,
Todd J. Lorenz,
Michael M. Kitt,
Neal S. Kleiman,
David Talley,
Frank Aguirre,
Charles J. Davidson,
John Paul Runyon,
James E. Tcheng
Publication year - 2001
Publication title -
circulation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 7.795
H-Index - 607
eISSN - 1524-4539
pISSN - 0009-7322
DOI - 10.1161/hc2901.093504
Subject(s) - eptifibatide , bolus (digestion) , medicine , pharmacokinetics , microgram , pharmacodynamics , pharmacology , anesthesia , percutaneous coronary intervention , chemistry , in vitro , biochemistry , myocardial infarction
Pharmacodynamics of eptifibatide, a cyclic heptapeptide antagonist of platelet glycoprotein IIb/IIIa, are substantially altered by anticoagulants that chelate calcium, resulting in overestimation ex vivo of the in vivo effects of this agent. We conducted a dose-ranging study to characterize the pharmacodynamics and pharmacokinetics of eptifibatide under physiological conditions.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom